Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MYMD Stock Summary
Top 10 Correlated ETFs
MYMD
In the News
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or the “Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a confer.
ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
BALTIMORE--( BUSINESS WIRE )--MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England. Results from preclinical and clinical studies showed that MYMD-1 was safe and well-tolerated in healthy subjects and significantly reduced inflammation in a mouse model compared to the widely used arthritis treatment etanercept (Enbrel®). These findings support the continued evaluation of MYMD-1® for autoimmune and inflammatory disorders.
What to Know About Buying Penny Stocks on July 11th
Here's what you need to know about trading penny stocks on July 11th The post What to Know About Buying Penny Stocks on July 11th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Benchmark Company Discovery Conference Date: December 2, 2021 Format: 1-on-1 meetings (virtual) Registration: Click here Benzinga Global Small Cap Conference Dates: December 8-9, 2021 Format: Present
Week 44 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An Edge
Two new Breakout Stocks for Week 44 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +68.8% YTD despite a record high 24 weeks out 43 weeks this year in negative conditions above the 40 MG level.
MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. The conference is being held at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida. MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D.
MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD's superior potency over CBD by factor of 8,000 times. Supera-CBD is MyMD's pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. The study was conducted by Eurofins D
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1's function in delaying aging early in the fourth quarter of 2021. Interim efficacy analysis from this study is expected in the first quarter of 2022. The primary goal of this Phase 2 double-blind, placebo-controlled clinical trial is to ach
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,096,933 titled “Method of Treating Disorders Associated with Chronic Inflammation.” The '933 patent becomes the thirteenth patent protecting the Company's lead cand
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.” The patent protects the Company's drug candidate Supe
MYMD Financial details
MYMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.64 | 154.44 | 0 | 0 | 0 | |
Net income per share | -23.73 | -380.79 | -0.29 | -0.85 | -0.39 | |
Operating cash flow per share | -18.63 | -301.08 | -0.13 | -0.56 | -0.32 | |
Free cash flow per share | -18.78 | -301.08 | -0.13 | -0.6 | -0.32 | |
Cash per share | 11.93 | 948.17 | 0.45 | 0.33 | 0.12 | |
Book value per share | 12.76 | 916.19 | -0.14 | 0.68 | 0.38 | |
Tangible book value per share | 12.23 | 914.39 | -0.14 | 0.38 | 0.11 | |
Share holders equity per share | 12.76 | 916.19 | -0.14 | 0.68 | 0.38 | |
Interest debt per share | 0 | 96.99 | 0.14 | 0.02 | 0 | |
Market cap | 744.03M | 1.96M | 4.43B | 6.37B | 1.34B | |
Enterprise value | 743.85M | 2.43M | 4.44B | 6.37B | 1.34B | |
P/E ratio | -68.58 | -0.5 | -415.18 | -213.06 | -88.64 | |
Price to sales ratio | 446.71 | 1.24 | 0 | 0 | 0 | |
POCF ratio | -87.35 | -0.64 | -950.77 | -326.19 | -109.17 | |
PFCF ratio | -86.66 | -0.64 | -950.77 | -304.64 | -109.17 | |
P/B Ratio | 127.54 | 0.21 | -843.43 | 269.21 | 91.15 | |
PTB ratio | 127.54 | 0.21 | -843.43 | 269.21 | 91.15 | |
EV to sales | 446.6 | 1.54 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -70.08 | -0.73 | -536.14 | -225.8 | -88.09 | |
EV to operating cash flow | -87.33 | -0.79 | -951.62 | -326.17 | -109.12 | |
EV to free cash flow | -86.64 | -0.79 | -951.62 | -304.62 | -109.12 | |
Earnings yield | -0.01 | -1.98 | 0 | 0 | -0.01 | |
Free cash flow yield | -0.01 | -1.57 | 0 | 0 | -0.01 | |
Debt to equity | 0 | 0.11 | -0.79 | 0.01 | 0.01 | |
Debt to assets | 0 | 0.09 | 6.11 | 0.01 | 0.01 | |
Net debt to EBITDA | 0.02 | -0.14 | -0.48 | 0.01 | 0.04 | |
Current ratio | 3.38 | 6.74 | 0.06 | 12.18 | 1.95 | |
Interest coverage | 0 | 0 | -7.96 | -47.35 | 178.9 | |
Income quality | 0.79 | 0.91 | 0.49 | 0.65 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.4 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.64 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.03 | 0 | 0 | 0.42 | 0.6 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0.07 | 0 | |
Capex to revenue | -0.04 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.29 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.03 | 2.27 | 0 | 0 | 0 | |
Graham number | 82.53 | 2.8K | 0.96 | 3.6 | 1.82 | |
ROIC | -1.16 | -0.32 | 17.87 | -1.2 | -1.01 | |
Return on tangible assets | -1.43 | -0.36 | -15.78 | -2.09 | -2.15 | |
Graham Net | 8.54 | 811.24 | 0.3 | 0.3 | 0.05 | |
Working capital | 4.7M | 8.78M | -2.2M | 11.63M | 2.63M | |
Tangible asset value | 5.59M | 9.34M | -5.26M | 13.15M | 4.2M | |
Net current asset value | 4.7M | 8.78M | -5.78M | 11.5M | 2.56M | |
Invested capital | 0 | 0.11 | -0.79 | 0.01 | 0.01 | |
Average receivables | 896.16K | 109.6K | 621.45K | 600K | 0 | |
Average payables | 837.68K | 642.94K | 1.2M | 1.33M | 1.61M | |
Average inventory | 1.22M | 392.13K | -653.08K | -752.57K | 0 | |
Days sales outstanding | 38.64 | 9.92 | 0 | 0 | 0 | |
Days payables outstanding | 162.91 | 2.95K | 22.33K | 0 | 0 | |
Days of inventory on hand | 138.87 | 980.63 | -18.65K | 0 | 0 | |
Receivables turnover | 9.45 | 36.78 | 0 | 0 | 0 | |
Payables turnover | 2.24 | 0.12 | 0.02 | 0 | 0 | |
Inventory turnover | 2.63 | 0.37 | -0.02 | 0 | 0 | |
ROE | -1.86 | -0.42 | 2.03 | -1.26 | -1.03 | |
Capex per share | -0.15 | 0 | 0 | -0.04 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.09 | -0.09 | -0.01 | -0.1 | 0.09 | |
Operating cash flow per share | -0.1 | -0.06 | -0.1 | -0.1 | -0.07 | |
Free cash flow per share | -0.1 | -0.06 | -0.1 | -0.1 | -0.07 | |
Cash per share | 0.18 | 0.12 | 0.39 | 0.29 | 0.19 | |
Book value per share | 0.47 | 0.38 | 0.35 | 0.27 | 0.36 | |
Tangible book value per share | 0.2 | 0.11 | 0.09 | 0.01 | 0.12 | |
Share holders equity per share | 0.47 | 0.38 | 0.35 | 0.27 | 0.36 | |
Interest debt per share | 0 | 0 | -0.02 | 0 | 0 | |
Market cap | 3.06B | 1.34B | 2.05B | 1.82B | 798.3M | |
Enterprise value | 3.06B | 1.34B | 2.05B | 1.82B | 798.09M | |
P/E ratio | -208.71 | -90.92 | -1.18K | -108.92 | 49.36 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -747.99 | -595.75 | -516.92 | -463.24 | -252.91 | |
PFCF ratio | -747.99 | -595.75 | -516.92 | -463.24 | -252.91 | |
P/B Ratio | 166.82 | 91.15 | 146.57 | 169.04 | 49.56 | |
PTB ratio | 166.82 | 91.15 | 146.57 | 169.04 | 49.56 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -827.25 | -357.92 | -563.52 | -251.48 | -68.86 | |
EV to operating cash flow | -747.96 | -595.48 | -516.9 | -463.24 | -252.84 | |
EV to free cash flow | -747.96 | -595.48 | -516.9 | -463.24 | -252.84 | |
Earnings yield | 0 | 0 | 0 | 0 | 0.01 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0.01 | 0.01 | 0 | 0 | 0 | |
Net debt to EBITDA | 0.04 | 0.16 | 0.02 | 0 | 0.02 | |
Current ratio | 4.54 | 1.95 | 10.02 | 5.41 | 1.71 | |
Interest coverage | -240.08 | 60.91 | 2.4 | 0 | 0 | |
Income quality | 1.11 | 0.6 | 2.63 | 0.94 | -0.78 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | -0.37 | -0.04 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.52 | 0.6 | 0.37 | 0.42 | 0.48 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1 | 0.9 | 0.29 | 0.79 | 0.85 | |
ROIC | -0.2 | -0.25 | -0.05 | -0.51 | -0.17 | |
Return on tangible assets | -0.38 | -0.52 | -0.02 | -0.28 | 0.36 | |
Graham Net | 0.13 | 0.05 | 0.03 | -0.07 | 0.06 | |
Working capital | 6.3M | 2.63M | 14.66M | 10.71M | 4.04M | |
Tangible asset value | 7.83M | 4.2M | 3.51M | 243.23K | 5.61M | |
Net current asset value | 6.17M | 2.56M | 1.88M | -1.36M | 4.02M | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.01M | 1.87M | 1.78M | 1.43M | 1.5M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.2 | -0.25 | -0.03 | -0.39 | 0.25 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
MYMD Frequently Asked Questions
What is MyMD Pharmaceuticals, Inc. stock symbol ?
MyMD Pharmaceuticals, Inc. is a US stock , located in Baltimore of Md and trading under the symbol MYMD
What is MyMD Pharmaceuticals, Inc. stock quote today ?
MyMD Pharmaceuticals, Inc. stock price is $2.39 today.
Is MyMD Pharmaceuticals, Inc. stock public?
Yes, MyMD Pharmaceuticals, Inc. is a publicly traded company.